Drug Database
MO

moxisylyte hydrochloride (Erecnos / Icavex)

✓ Approved

Medea Research · Small Molecule · Small Molecule

What is moxisylyte hydrochloride?

moxisylyte hydrochloride is a small molecule developed by Medea Research. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesErecnos, Icavex
CompanyMedea Research
Drug ClassSmall Molecule
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Medea Research

Therapeutic Indications

moxisylyte hydrochloride is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersErectile dysfunction✓ Approved

Related Research Articles

PubMedJournal of virology2026-07-17

Cyclo-C stabilizes PEX13 to inhibit porcine epidemic diarrhea virus replication by blocking pexophagy-mediated disruption of antiviral innate immunity.

Lou Jinxiu J, Guo Zhiwei Z, Chen Kang K, Tian Yuanmingyue Y et al.

The persistent threat of porcine epidemic diarrhea virus (PEDV) to the global swine industry is compounded by high neonatal piglet mortality and the absence of effective antiviral therapies. Host-directed strategies that reinforce immunity offer a promising avenue to counter viral immune evasion. Through screening of an FDA-approved compound library, we identify the small-molecule cyclocytidine hydrochloride (Cyclo-C) as a potent inhibitor of PEDV replication that acts by stabilizing the peroxisomal biogenesis factor PEX13, a previously unrecognized host restriction factor. The antiviral activity of Cyclo-C is strictly PEX13-dependent, as it is completely abrogated in PEX13 knockout cells. Mechanistically, Cyclo-C disrupts the interaction between PEX13 and the viral nonstructural protein 8 (NSP8), thereby preventing NSP8-mediated PEX13 degradation and the subsequent induction of PI3K/AKT/mTOR-driven pexophagy. Preservation of peroxisomal integrity stabilizes the peroxisome-localized pool of MAVS, leading to a robust enhancement of type III interferon (IFN-III) responses that suppress viral replication. Critically, this mechanism translates in vivo, where Cyclo-C treatment of PEDV-challenged piglets significantly reduces mortality, lowers viral loads, and protects intestinal villus architecture. Our findings establish Cyclo-C as a first-in-class host-directed therapeutic candidate and validate the concept that pharmacological preservation of peroxisome-mediated innate immunity represents an effective antiviral strategy against enteric coronaviruses. The high genetic variability of porcine epidemic diarrhea virus (PEDV) limits current vaccine efficacy, and no antiviral therapeutics exist. Host-directed therapies targeting cellular pathways that viruses exploit for immune evasion offer an alternative approach. Here, we identify the FDA-approved compound Cyclo-C as a potent inhibitor of PEDV replication. Cyclo-C acts by stabilizing PEX13, a host protein that the virus degrades to evade immunity. By blocking viral protein NSP8 from binding PEX13, Cyclo-C prevents virus-induced pexophagy, thereby preserving peroxisomal integrity. This preserves peroxisome-localized MAVS and enhances type III interferon responses. In infected neonatal piglets, Cyclo-C reduced mortality and viral loads while protecting intestinal integrity. This study provides proof of concept that targeting peroxisomal immune regulation is a viable antiviral strategy and identifies Cyclo-C as a promising candidate for treating PEDV infection.

PMID 42466851
Read full article →
PubMedLuminescence : the journal of biological and chemical luminescence2026-07-16

Pioneering Novel, Green, White, and Blue Fluorescence-Based Platforms for Sustainable and Concurrent Monitoring of Ciprofloxacin With Celecoxib or Itopride in Biological Matrices.

Barakat Neamat T NT, El-Aziz Heba Abd HA, Eid Manal I MI, Ibrahim Fawzia A FA

Two innovative spectrofluorimetric techniques were developed for the first time to enable simultaneous quantification of ciprofloxacin hydrochloride in binary mixtures with either celecoxib or itopride hydrochloride in biological fluids. The first relied on synchronous spectrofluorimetry at a constant wavelength interval (Δλ = 100 nm), which effectively reduced spectral interference and allowed accurate estimation of celecoxib and ciprofloxacin hydrochloride at their zero-crossing points of 276 and 328 nm, respectively. The second technique leveraged direct spectrofluorimetric measurement of ciprofloxacin hydrochloride and itopride hydrochloride mixture, using excitation at 258 nm that yielded two discrete emission peaks at 351 nm for ITH and 441 nm for CPN. Both methods demonstrated remarkable sensitivity and selectivity, achieving excellent linearity (r = 0.9999) across broad ranges of (0.05-3.0 μg/mL and 0.05-5.0 μg/mL for ciprofloxacin hydrochloride and celecoxib, respectively, and 0.07-4.0 μg/mL for ciprofloxacin hydrochloride and 0.04-9.0 μg/mL for itopride hydrochloride. Comprehensive greenness assessment was performed, which confirmed their low environmental burden. Moreover, whiteness and blueness evaluations highlighted the favorable integration of analytical efficiency with sustainability principles. The proposed strategies combine rapidity, high sensitivity, and environmental safety, providing reliable alternatives for routine quality control of pharmaceutical formulations and accurate determination of CPN mixtures in biological matrices.

PMID 42458825
Read full article →
PubMedAnnals of hematology2026-07-16

Breast cancer risk in female survivors of Hodgkin lymphoma after exposure to non-pegylated liposomal doxorubicin at young adult and adult age: the first real-life series from Southern Italy cancer centers.

Picardi Marco M, Vincenzi Annamaria A, Giordano Claudia C, Pugliese Novella N et al.

Studies in female Hodgkin lymphoma (HL) survivors have shown that doxorubicin hydrochloride exposure at young adult and adult (YA&A) age is associated with an increased risk of breast cancer (BC) regardless of chest-radiotherapy (c-RT). Although non-pegylated liposomal doxorubicin (NPLD)-based regimens have shown efficacy and safety in the treatment of lymphoma, the association between NPLD exposure and BC risk has not been examined in HL survivors. We assessed standardized incidence ratio (SIR) and absolute excess risk (AER) of BC in a cohort of 100 female ≥ 5-year HL survivors treated between 18 and 60 years of age with NPLD-based regimen in tertiary hospitals in southern Italy between 2009 and 2020. The median cumulative liposomal doxorubicin dose was 290 mg/m²; c-RT was administered to 20% of patients. After a median follow-up of 10 years (interquartile range, 8-11 years), no women had developed BC. Compared with the Italian general population, the SIR was 0.00 (95% confidence interval, 0.00-4.29); the standardized ratio was 86.5 per 100,000 person per year according to the AIRTUM (Associazione Italiana Registri Tumori) Working Group data for women aged between 18 and 60 years. In our series, the AER was - 8.87 per 10,000 person per year. Based on data derived from the pooled summary rate of literature, HL survivors treated with doxorubicin hydrochloride-including regimens at YA&A age had an incidence rate of BC of 1.6% at 10-year median follow-up. These data, if validated in largest datasets with longer follow-up, suggest that treatment with NPLD could be not associated with increased BC risk in HL survivors, unlike conventional doxorubicin. Our findings provide a rationale for evaluating NPLD-based frontline therapy in prospective studies of YA&A patients with newly diagnosed HL.

PMID 42461398
Read full article →
PubMedBMC infectious diseases2026-07-16

Rare primary small intestinal infection: a case report of Mycobacterium kansasii enteropathy in an immunocompetent patient and literature review.

Wu Lang L, Wang Jiayao J, Zhu Jin J, Li Teng T et al.

Non-tuberculous mycobacteria (NTM) are important opportunistic pathogens that most commonly infect the lungs. Primary involvement of the gastrointestinal tract-especially the small intestine-is exceedingly rare, and small-bowel infection caused by Mycobacterium kansasii (M. kansasii) has seldom been reported. We describe an extremely rare case of primary small-intestinal M. kansasii infection in an immunocompetent young man who presented with prolonged chronic diarrhea and fever. After an extensive but unrevealing diagnostic work-up, the etiology was finally established by microbial metagenomic sequencing of tissue obtained by double-balloon endoscopy. Building on the initial regimen of ethambutol hydrochloride, rifampicin, and clarithromycin-and with subsequent antibiotic adjustments tailored to the patient's evolving symptoms-clinical symptoms resolved completely, and follow-up endoscopy showed mucosal improvement. This case underscores that NTM infection should be considered in the differential diagnosis of unexplained chronic gastrointestinal symptoms and highlights the pivotal role of modern molecular techniques in reaching a precise diagnosis. Detailed analysis of the case together with a review of the literature aims to raise clinicians' awareness and improve management of this rare entity.

PMID 42458280
Read full article →
PubMedAnnals of hematology2026-07-16

Peripheral blood CD8 + T-cell count at diagnosis predicts prognosis in R-CHOP-treated diffuse large B-cell lymphoma patients.

Chen Fang F, Liu Ping P, Zhao Jiajia J, Wang Demin D et al.

While the prognostic significance of peripheral blood (PB) lymphocyte counts in diffuse large B-cell lymphoma (DLBCL) patients treated with Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Prednisone (R-CHOP) is established, the specific role of CD8+ T-cell counts (CD8c) remains unclear. Methods: This retrospective study analyzed 315 newly diagnosed DLBCL patients treated at Central Hospital of Xiangtan from January 2018 to September 2023. We evaluated the prognostic significance of initial CD8c and other clinical parameters using univariate and multivariate survival analyses to identify independent predictors of outcome. An optimal CD8c cut-off value of 264.5×106/L was identified. Low CD8c correlated with significantly improved 5-year progression-free survival (PFS) (88.78% vs 49.18%, p<0.001) and overall survival (OS) (84.02% vs 31.25%, p<0.001). Multivariate analysis confirmed CD8c as an independent prognostic factor for both PFS and OS. CD8c demonstrated significant interactions with lactate dehydrogenase levels. Notably, low CD8c groups consistently exhibited superior survival outcomes, even in the presence of other poor prognostic factors. Initial PB CD8c serves as an independent predictor for R-CHOP-treated DLBCL patients. These findings suggest CD8c may be a candidate for enhancing existing prognostic models, particularly when combined with established risk factors, underscoring the potential importance of host immune status in DLBCL prognosis and treatment outcomes. Independent validation in external cohorts is needed.

PMID 42458006
Read full article →
PubMedMedical science monitor : international medical journal of experimental and clinical research2026-07-15

Effect of Dexmedetomidine Hydrochloride Nasal Spray on Anxiety and Sleep in Patients Undergoing Gynecological Laparoscopic Surgery.

Zhao Lin L, Zhang Xiaotian X, Li Xiaoxiao X, He Yipeng Y et al.

BACKGROUND Postoperative sleep disturbances are common after gynecological laparoscopic surgery, possibly delaying recovery. This study evaluated whether additional postoperative administration of dexmedetomidine hydrochloride nasal spray could improve anxiety, sleep quality, and early recovery in patients who routinely received preoperative dexmedetomidine hydrochloride nasal spray. MATERIAL AND METHODS In this prospective, single-blind, randomized, controlled, single-center study, 80 patients undergoing elective gynecological laparoscopic surgery were enrolled from June 2024 to December 2024 and randomized to a control group (n=40) or dexmedetomidine group (n=40). Both groups received 50 μg dexmedetomidine hydrochloride nasal spray 30 minutes before anesthesia. The dexmedetomidine group received an additional 75 μg at 9: 30 PM on the night of surgery. Anxiety was assessed using the Hamilton Anxiety Scale (HAMA). Sleep was evaluated using the Athens Insomnia Scale (AIS) and sleep wristbands. RESULTS Baseline characteristics, postoperative pain, and postoperative nausea and vomiting were comparable between groups (all P>0.05). Both groups showed significantly decreased HAMA scores after preoperative medication compared with baseline (both P<0.001). Compared with controls, the dexmedetomidine group showed no significant difference in total AIS score on the night of surgery (P=0.771), but had a higher proportion of patients without subjective sleep deterioration (25.0% vs 5.0%, P=0.012), longer total sleep time (P=0.030), higher proportion of deep sleep (P=0.040), fewer awakenings (P=0.020), and shorter postoperative hospital stay (P<0.001). CONCLUSIONS Additional dexmedetomidine hydrochloride nasal spray on the night after surgery improved objective sleep structure and reduced subjective sleep deterioration without increasing adverse reactions.

PMID 42452824
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about moxisylyte hydrochloride